Examination of the relationship of image on the morphological changes and prognosis by XELOX + bevacizumab therapy in the healing unresectable advanced or recurrent colorectal cancer with liver metastasis - Examination of the relationship of image on the morphological changes and prognosis by XELOX + bevacizumab therapy in the healing unresectable advanced or recurrent colorectal cancer with liver metastasis

Yokohama City University Hospital0 sites50 target enrollmentSeptember 3, 2014

Conditionscolon cancer

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: colon cancer
Sponsor: Yokohama City University Hospital
Enrollment: 50
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

September 3, 2014

End Date

TBD

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Yokohama City University Hospital

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•(1\) On the image, brain metastases are found, or from clinical symptoms, brain metastasis is suspected. (2\) Cerebrovascular neuropathy, or with a history within one year prior to enrollment. It has been conducted surgery within 4 weeks. (3\)Prior to enrollment, biopsy with incision, the suture treatment for trauma, or have implemented fine\-needle aspiration cytology within 1 week. (4\) Traumatic fracture not healing (5\) Bleeding tendency, or to have a coagulopathy. (6\)The administration of an anti\-thrombotic agent for thrombosis within 10 days before registration (7\) Require the administration of aspirin formulation of 325 mg or more. (8\) It has with symptoms at the time of registration and the (corresponding to grade 2 or more in Ver.3\.0 Japanese translation JCOG / JSCO version NCI\-CTCAE) heart disease or are doing some kind of treatment. Alternatively, there is a history of myocardial infarction within one year prior to enrollment. (9\) on the image, a body cavity fluid requiring treatment. (10\)Digestive cancer carcinoma in situ of the cervix and skin basal cell carcinoma, or by endoscopic mucosal resection endoscopic, healing has been confirmed, transition is not observed overlap cancer of less than five years was (healing disease\-free interval it has to a) except for the prostate cancer (11\) And has a neuropathy of grade 1 or more Ver.3\.0 Japanese translation JCOG / JSCO version NCI\-CTCAE (12\)Pregnant women, lactating women, pregnancy test positive. Or, patients with no intention to contraception. (13\) Oxaliplatin, or with a history of hypersensitivity to severe capecitabine (14\) Suspected (DPD) deficiency dihydropyrimidine dehydrogenase, adverse reactions to fluoropyrimidine drugs was expressed. (15\)Investigator deems inappropriate to participate in the test (16\)The cases with serious complications (uncontrolled digestive ulcer, hypertension, diarrhea, infections, gastrointestinal perforation, such as interstitial pneumonia or pulmonary fibrosis)